NPLATE Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NPLATE
| Patents: | 4 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for NPLATE |
Recent Clinical Trials for NPLATE
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Anjali Sharathkumar | Early Phase 1 |
| Amgen | Early Phase 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
Pharmacology for NPLATE
| Mechanism of Action | Thrombopoietin Receptor Agonists |
| Physiological Effect | Increased Megakaryocyte Maturation Increased Platelet Production |
| Established Pharmacologic Class | Thrombopoietin Receptor Agonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NPLATE Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NPLATE Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NPLATE Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2033-03-11 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2034-11-21 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2039-02-26 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2031-04-05 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2035-10-02 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for NPLATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 348163 | See Plans and Pricing |
| Mexico | PA01003873 | See Plans and Pricing |
| Australia | 5943201 | See Plans and Pricing |
| Hong Kong | 1090932 | See Plans and Pricing |
| Austria | 380828 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NPLATE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 91598 | Luxembourg | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM (NPLATE - ROMIPLOSTIM) |
| C01124961/01 | Switzerland | See Plans and Pricing | FORMER REPRESENTATIVE: BOHEST AG, CH |
| PA2009006,C1124961 | Lithuania | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| 25/2009 | Austria | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| 2009/022 | Ireland | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
